Concord Biotech: sales recovery is visible, but watch how much becomes earnings

Concord Biotech's business recovery is drawing renewed attention in November 7 coverage. Its own September-quarter presentation gives readers a more useful question than whether sales are growing: how much of the extra revenue is turning into operating earnings, and which profit figure is being compared?

The results discussed here were disclosed in October. This article reviews those figures in the context of the fresh coverage; it does not describe a new results announcement on November 7. News context: BusinessLine.

Sales recovery and margin recovery are different

The company's Q2 FY27 presentation reports consolidated revenue of ₹309.1 crore, compared with ₹247.1 crore a year earlier. It reports EBITDA of ₹104.4 crore against ₹88.5 crore, and total consolidated profit after tax of ₹69.6 crore against ₹63.1 crore. The presentation gives year-on-year growth of 25.1%, 18.0% and 10.3% respectively. Figures here are rounded as shown in that document. Source: Concord's Q2 FY27 presentation, consolidated profit-and-loss table.

Our calculation: the extra ₹62 of sales did not become ₹62 of earnings

Using those rounded figures, revenue increased by ₹62.0 crore, while EBITDA increased by ₹15.9 crore. The ratio of the two increases is approximately 25.6%. This is an incremental comparison for these two quarters, not the company's reported EBITDA margin or a forecast of future profitability.

The reported EBITDA margin moved from 35.8% to 33.8%, a decline of 2 percentage points. That means approximately ₹2 less EBITDA per ₹100 of sales on the reported rounded margin measure, despite the larger revenue base.

Sensitivity illustration: applying the earlier 35.8% margin to ₹309.1 crore of revenue produces about ₹110.7 crore of EBITDA. Compared with the reported ₹104.4 crore, the difference is roughly ₹6.3 crore. This holds one variable constant to explain the effect of margin; it is not an earnings estimate, a management target or an assertion that all of the difference is recoverable.

Why different screens can display different profit numbers

The exchange filing separately identifies total consolidated profit and the amount attributable to owners of the parent. They are different accounting rows. This article uses the company's presentation measure of total consolidated PAT for its year-on-year comparison; it does not substitute parent-attributable profit into that series. Also keep standalone and consolidated results separate. Source: NSE integrated consolidated filing.

Before calculating a margin or growth rate, write the period, unit and profit definition above the numbers. For example, ₹30,907.02 lakh of revenue in the exchange filing equals ₹309.0702 crore. A lakh-to-crore conversion error would overwhelm any genuine change in the business.

What would make the recovery more convincing?

• Conversion: examine whether operating earnings begin to keep pace with revenue over subsequent comparable periods.
• Cash: reconcile profit with operating cash flow, receivables and inventory instead of treating reported earnings as cash already collected.
• Investment: track spending and execution against disclosed milestones; a growth opportunity is not yet a realised return.
• Consistency: use the same consolidation basis, reporting window and corporate-action adjustments when comparing per-share figures.

The current figures support a distinction: sales have grown faster than operating earnings and total PAT. Whether the next phase improves that conversion is the evidence to watch, rather than assuming a rising top line settles the investment case.